Phaseline

Companies › Suzhou Centergene Pharmaceuticals

Suzhou Centergene Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SJ04
Recombinant human chorionic gonadotropin (hCG) analog
–Phase 1Assisted Reproductive TechnologyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06599528SJ04Phase 1Assisted Reproductive TechnologyGenitourinaryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.